|Bid||10.05 x 21500|
|Ask||10.49 x 2200|
|Day's Range||9.99 - 10.54|
|52 Week Range||9.99 - 17.62|
|Beta (3Y Monthly)||2.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.50|
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / U.S. equities saw losses on Tuesday as continued weakness in oil prices pressured energy stocks lower. Crude oil dropped for the 12th consecutive session, ...
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9. On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which is ~19% below its 52-week high of $184.00 on June 20.
CRANBURY, N.J., Nov. 12, 2018 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -14.81% and -11.63%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cranbury, New Jersey-based company said it had a loss of 84 cents per share. Losses, adjusted for costs related to mergers and acquisitions, were 31 cents per share. The results did not meet Wall Street ...
U.S. Galafold® (Migalastat) Fabry Launch Tracking Significantly Ahead of Expectations- 100+ Patients Prescribed Galafold Since August Launch 3Q18 Global Galafold Net Product.
NEW YORK, NY / ACCESSWIRE / October 29, 2018 / U.S. equities rolled back on Friday as disappointing corporate earnings added to the bearish sentiment in the market. The Dow Jones Industrial Average shed ...
CRANBURY, N.J., Oct. 29, 2018 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 5,.
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
As we recently mentioned, biotech stocks have been particularly hammered over the last few weeks. Unfortunately, that’s meant that many biotech stocks have been hit hard. The market rout has caused many biotech stocks to drop to single or low double-digit prices.
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...
Management and External Thought Leaders to HighlightRobust Portfolio of Novel Therapies for Rare Metabolic Diseases Webcast Scheduled from 8:30am – 12:30pm E.T. CRANBURY,.
Amicus Therapeutics (FOLD) today announced a major collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (Penn) to pursue research and development of novel gene therapies for Pompe disease, Fabry disease, CDKL5 deficiency and one additional undisclosed rare metabolic disorder. This relationship will combine Amicus’ protein engineering and glycobiology expertise with Penn’s adeno associated virus (AAV) gene transfer technologies to develop AAV gene therapies designed for optimal cellular uptake, targeting, dosing, safety and manufacturability.
Amicus Therapeutics (FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells. Patients treated with AT-GAA for up to 18 months showed improvements in six-minute walk test (6MWT) distance and other measures of motor function and muscle strength, stability or increases in forced vital capacity (FVC), and durable reductions in biomarkers of muscle damage and disease substrate.
CRANBURY, N.J., Oct. 02, 2018 -- Amicus Therapeutics (Nasdaq:FOLD), today announced that an oral presentation and a poster highlighting its development program AT-GAA for Pompe.
In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).
NEW YORK, NY / ACCESSWIRE / September 27, 2018 / U.S. markets fell sharply Wednesday after the Federal Reserve raised interest rates and indicated another increase would be coming in December. The Nasdaq Composite Index decreased 0.21 percent to close at 7,990.37. “It was virtually a foregone conclusion, and that may cause some investors to scratch their heads a bit given all the uncertainty in the market, with trade barbs flying, an unstable housing market, and ballooning federal debt,” according to Mike Loewengart, vice president of investment strategy at E-Trade Financial Corp. “But the Fed needs to build up its toolbox to address a variety of economic conditions, which makes getting back to a normalized rate environment so important.
CRANBURY, N.J., Sept. 26, 2018-- Amicus Therapeutics today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Leerink Partners ...
NEW YORK, Sept. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Inc. said it has agreed to acquire clinical-stage gene therapy company Celenex for $100 million in cash, giving the publicly traded biotechnology company entry into gene therapies. Celenex has licensed a few pivotal and potentially first-to-market gene therapy programs to fight Batten disease, a fatal disorder that affects the nervous system in children. Under the acquisition agreement, Celenex’s shareholders are eligible for up to $277 million if significant development, submission and approval milestones are met, and up to $75 million in tiered sales.
The New Jersey based biotech company, Amicus Therapeutics, was founded in 2002 by a father looking to find a cure for his children. Yahoo Finance’s Alexis Christoforous sits down with its founder and CEO, John Crowley.